Sermorelin
Mechanism.
Sermorelin is a synthetic peptide consisting of the first 29 amino acids of the 44-amino-acid growth hormone-releasing hormone (GHRH). It was FDA-approved in 1997 (as Geref) for the diagnosis and treatment of growth hormone deficiency in children, though the branded product was discontinued for commercial reasons (not safety concerns). It stimulates the pituitary gland to produce and release growth hormone in a physiological, pulsatile manner, and is now widely used off-label through compounding pharmacies for adult growth hormone optimization.
If growth hormone is like water from a faucet, direct GH injection is like pouring water from a bucket -- you get a big splash all at once, and the body's natural flow-control valve gets bypassed. Sermorelin instead taps the faucet handle, asking your body to turn the water on naturally, at its own pace, with the safety valve still working.
How it's taken.
Values below describe how Sermorelin has been administered in published trials and labeling. Provided for educational purposes only — this is not medical advice and not instructions for self-administration. Consult your healthcare provider before making any health decision.
GHRH analogue (1-29 fragment). Was FDA-approved (Geref) for GH deficiency diagnosis, but withdrawn from market. Now available through compounding pharmacies. Produces physiologic pulsatile GH release. Often combined with GHRP.
Use the free peptide calculator for dilution, unit conversion, and injection volume.
Side effects, rare serious events, who shouldn't.
How strong is the evidence?
Scores derived from rating, indexed studies, regulatory status, and catalogued safety data for this peptide. Curated per-peptide scoring replaces this when available.
Every study we cite.
Each study with its published finding and a plain-language note on limitations or funding.